MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS

Year 2022, , 537 - 550, 29.05.2022

Songul Tezcan

https://doi.org/10.33483/jfpau.1039307

Abstract

Objective: Colon cancer is the third most common cancer type globally and usually occurs at advanced ages. Since the risk of comorbid diseases may also increase with age, colon cancer patients have an increased risk of polypharmacy. Hypertension, chronic obstructive pulmonary disease, diabetes, and cardiovascular disease are the frequently seen comorbidities in cancer patients. Patients who are elderly, have comorbid conditions, and are taking two or more medications are at higher risk for drug-drug interactions (DDIs). Additionally, cancer patients frequently use many drugs such as supportive care drugs for the treatment of side effects of cytotoxic drugs. DDIs may cause therapeutic failure or potentially serious adverse events. determination and evaluation of DDI levels identify the most suitable rational therapy for cancer patients.

Result and Discussion: This study has reviewed the drugs used to treat colon cancer (Capecitabine, Fluorouracil, Irinotecan, Oxaliplatin, Bevacizumab, Ziv-Aflibercept, Nivolumab, Pembrolizumab, Ramucirumab, Regorafenib, Larotrectinib, Dabrafenib, Trametinib, Trifluridine and tipiracil, and Encorafenib) and determined the possible drug-drug interactions. This study will help the pharmacists and clinicians to evaluate possible interactions.

Keywords

colon cancer, comorbidity, drug-drug interactions, management, polypharmacy

KOLON KANSERI HASTALARINDA İLAÇ ETKİLEŞİMLERİNİN YÖNETİMİ

Abstract

Amaç: Kolon kanseri, dünya çapında en yaygın üçüncü kanser türüdür ve genellikle ileri yaşlarda ortaya çıkar. Yaşla birlikte komorbid hastalık riski de artabileceğinden, kolon kanseri hastalarının polifarmasi riski artmıştır. Hipertansiyon, kronik obstrüktif akciğer hastalığı, diyabet ve kardiyovasküler hastalık, kanser hastalarında sık görülen komorbiditelerdir. Yaşlı, komorbid rahatsızlıkları olan ve iki veya daha fazla ilaç alan hastalar, ilaç-ilaç etkileşimleri (İİE) için daha yüksek risk altındadır. Ayrıca kanser hastaları, sitotoksik ilaçların yan etkilerinin tedavisi için sıklıkla destekleyici bakım ilaçları gibi birçok ilacı kullanmaktadır. İİE'ler terapötik başarısızlığa veya potansiyel olarak ciddi yan etkilere neden olabilir. İİE düzeylerinin belirlenmesi ve değerlendirilmesi, kanser hastaları için en uygun akılcı tedavinin sağlanmasında yardımcı olmaktadır.

Sonuç ve Tartışma: Bu çalışmada, kolon kanseri tedavisinde kullanılan ilaçlar (Kapesitabin, Fluorourasil, irinotecan, oksaliplatin, bevasizumab, ziv-aflibersept, nivolumumab, pembrolizumab, ramusirumab, regorafenib, larotrektinib, dabrafenib, trametinib, trifluridin ve tipirasil ve enkorafenib) incelenmiş ve olası ilaç etkileşimleri belirlenmiştir. Bu çalışma eczacıların ve klinisyenlerin olası etkileşimleri değerlendirmesine yardımcı olacaktır.

Keywords

ilaç-ilaç etkileşimleri, kolon kanseri, komorbidite, polifarmasi, yönetim

References

• 1. Laban, A. A., Birand, N., Chukwunyere, U., Abdi, A., & Basgut, B. (2021). Evaluation of drug-drug interactions in cancer patients treated at a university hospital in North Cyprus using two interaction databases. Nigerian journal of clinical practice, 24(7), 1067–1071. [CrossRef] https://doi.org/10.4103/njcp.njcp_266_20
• 2. Lavan, A. H., O'Mahony, D., Buckley, M., O'Mahony, D., & Gallagher, P. (2019). Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability. The oncologist, 24(9), e968–e977. [CrossRef] https://doi.org/10.1634/theoncologist.2018-0476
• 3. Montané, E., & Castells, X. (2021). Epidemiology of drug-related deaths in European hospitals: A systematic review and meta-analysis of observational studies. British journal of clinical pharmacology, 87(10), 3659–3671. [CrossRef] https://doi.org/10.1111/bcp.14799
• 4. Ismail, M., Khan, S., Khan, F., Noor, S., Sajid, H., Yar, S., & Rasheed, I. (2020). Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC cancer, 20(1), 335. [CrossRef] https://doi.org/10.1186/s12885-020-06855-9 5. Capecitabine. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 6. https://reference.medscape.com/drug/xeloda-capecitabine-342211#3 Accessed Date: 18 Feb 2021
• 7. Fluorouracil. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 8. https://reference.medscape.com/drug/adrucil-fluorouracil-342092#3 Accessed Date: 18 Feb 2021
• 9. Ramírez, J., House, L. K., Karrison, T. G., Janisch, L. A., Turcich, M., Salgia, R., Ratain, M. J., & Sharma, M. R. (2019). Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. Journal of clinical pharmacology, 59(12), 1632–1640. [CrossRef] https://doi.org/10.1002/jcph.1476
• 10. Salvador-Martín, S., García-González, X., García, M. I., Blanco, C., García-Alfonso, P., Robles, L., Grávalos, C., Pachón, V., Longo, F., Martínez, V., Sanjurjo-Sáez, M., & López-Fernández, L. A. (2018). Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacological research, 136, 133–139. [CrossRef] https://doi.org/10.1016/j.phrs.2018.08.026
• 11. Fujita, K., Matsumoto, N., Ishida, H., Kubota, Y., Iwai, S., Shibanuma, M., & Kato, Y. (2019). Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure. Current drug metabolism, 20(5), 361–376. [CrossRef] https://doi.org/10.2174/1389200220666190402143125
• 12. de Man, F. M., Goey, A., van Schaik, R., Mathijssen, R., & Bins, S. (2018). Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clinical pharmacokinetics, 57(10), 1229–1254. [CrossRef] https://doi.org/10.1007/s40262-018-0644-7
• 13. Irinotecan. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 14. https://reference.medscape.com/drug/camptosar-irinotecan-342252#3 Accessed Date: 18 Feb 2021
• 15. Oxaliplatin. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 16. Barlow, A., Prusak, E. S., Barlow, B., & Nightingale, G. (2021). Interventions to reduce polypharmacy and optimize medication use in older adults with cancer. Journal of geriatric oncology, 12(6), 863–871. [CrossRef] https://doi.org/10.1016/j.jgo.2020.12.007
• 17. Bevacizumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 18. https://reference.medscape.com/drug/avastin-mvasi-bevacizumab-342257#11 Accessed Date: 18 Feb 2021
• 19. Ziv-Aflibercept. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 20. https://reference.medscape.com/drug/zaltrap-ziv-aflibercept-999765#5 Accessed Date: 18 Feb 2021
• 21. Nivolumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 22. https://reference.medscape.com/drug/opdivo-nivolumab-999989#3 Accessed Date: 18 Feb 2021
• 23. Pembrolizumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 24. https://reference.medscape.com/drug/keytruda-pembrolizumab-999962 Accessed Date: 18 Feb 2021
• 25. Ramucirumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 26. https://reference.medscape.com/drug/cyramza-ramucirumab-999926 Accessed Date: 18 Feb 2021
• 27. Regorafenib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 28. https://reference.medscape.com/drug/stivarga-regorafenib-999774#3 Accessed Date: 18 Feb 2021
• 29. Larotrectinib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 30. https://reference.medscape.com/drug/vitrakvi-larotrectinib-1000260#3 Accessed Date: 18 Feb 2021
• 31. Dabrafenib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 32. https://reference.medscape.com/drug/tafinlar-dabrafenib-999853#3 Accessed Date: 18 Feb 2021
• 33. Yin, H., Wang, Z., Wang, X., Lv, X., Fan, X., Yan, M., Jia, Y., Jiang, L., Cao, J., & Liu, Y. (2021). Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions. Biomedical chromatography : BMC, 35(11), e5205. [CrossRef] https://doi.org/10.1002/bmc.5205
• 34. Trametinib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
• 35. https://reference.medscape.com/drug/mekinist-trametinib-999854#5 Accessed Date: 18 Feb 2021
• 36. Trifluridine and tipiracil. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 19 Nov 2021). Available from: http://online.lexi.com. Subscription required to view.
• 37. Kopetz, S., Grothey, A., Yaeger, R., Cutsem, E.V., Desai, J., Yoshino, T. et al. (2019) Encorafenib, binimetinib, and cetuximab in BRAFV600E-mutated colorectal cancer. N Engl J Med. 381[17):1632-1643. [CrossRef] doi:10.1056/NEJMoa1908075.
• 38. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T. et al. Encorafenib plus cetuximab as a newstandard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer:updated survival results and subgroup analyses from the BEACON study. J Clin Oncol,2021;39[4):273-284. [CrossRef] doi:10.1200/JCO.20.02088
• 39. Encorafenib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 19 Nov 2021). Available from: http://online.lexi.com. Subscription required to view.
• 40. Moghaddas, A., Adib-Majlesi, M., Sabzghabaee, A. M., Hajigholami, A., & Riechelmann, R. (2021). Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27(1), 46–53. [CrossRef] https://doi.org/10.1177/1078155220910209
• 41. Mouzon, A., Kerger, J., D'Hondt, L., & Spinewine, A. (2013). Potential interactions with anticancer agents: a cross-sectional study. Chemotherapy, 59(2), 85–92. [CrossRef] https://doi.org/10.1159/000351133
• 42. Venkatesh, K.M., Swathi, A., Rajendra, H. (2021) Assessment of potential drug - Drug interaction among the patients receiving cancer chemotherapy: A cross-sectional study. Journal of Pharmacology and Pharmacotherapeutics. 12 (2):79-85[CrossRef] doi: 10.4103/jpp.jpp_16_21